Change in the primary and secondary end points over the study period
| Medical treatment (n=18) | Ablation (n=20) | Ablation vs medical treatment p Value | |||
| Baseline (mean/SD) | Change at end of study (mean/SD) | Baseline (mean/SD) | Change at end of study (mean/SD) | ||
| CMR | N=18 | N=19 | |||
| LVEF (%) | 42.9 (9.6) | 36.1 (11.9) | |||
| Change in LVEF in first week | +1.1 (4.5) | +5.5 (9.9) | 0.1 | ||
| Change in LVEF at end of study | +2.8 (6.7) | +4.5 (11.1) | 0.6 | ||
| LVESV (ml) | 126.3 (58.4) | −10.6 (32.2) | 163.8 (83.2) | −20 (50.2) | 0.5 |
| LVEDV (ml) | 215.0 (74.7) | −9.35 (35.7) | 244.1 (94.0) | −12.6 (51.7) | 0.8 |
| LAEDA (mm2) | 3214.5 (594.1) | +35.5 (364.0) | 3291.1 (766.1) | −237.0 (490.4) | 0.06 |
| RNVG | N=17 | N=20 | |||
| LVEF (%) | 19.6 (5.9) | +1.4 (5.9) | 15.1 (6.5) | +8.2 (12.0) | 0.032 |
| RVEF (%) | 21.5 (6.2) | +1.2 (4.9) | 18.4 (7.9) | +4.3 (8.1) | 0.17 |
| QoL | N=18 | N=20 | |||
| KCCQ | 37.1 (19.5) | +5.6 (14.0) | 42.1 (16.5) | +7.1 (21.1) | 0.81 |
| MLHFQ | 59.2 (22.4) | −2.8 (17.9) | 55.8 (19.8) | −5.7 (19.7) | 0.65 |
| SF-36 PCS | 30.3 (7.1) | −1 (4.4) | 30.3 (9.2) | +4 (9.5) | 0.042 |
| SF-36 MCS | 37.1 (14.0) | +5.9 (8.5) | 40.7 (10.2) | +0.4 (9.5) | 0.07 |
| 6 min walk | N=15 | N=17 | |||
| Distance (m) | 351.8 (117.1) | +21.4 (77.4) | 317.5 (125.8) | +20.1 (76.5) | 0.96 |
| NT-proBNP | N=18 | N=20 | |||
| pg/ml | 1846 (1687) | +85 (648) | 2550 (2150) | −196 (1469) | 0.45 |
CMR, cardiac MRI; KCCQ, Kansas City Cardiomyopathy Questionnaire; LAEDA, left atrial end-diastolic area; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NT-pro BNP, N-terminal pro-brain-type natriuretic peptide; QoL, quality of life; RNVG, radionuclide ventriculography; RVEF, right ventricular ejection fraction; SF-36 MCS, Short Form-36 mental component summary; SF-36 PCS, Short Form-36 physical component summary.